Testimonials
“[HASP] represents a paradigm shift in the approach to storage of red cells, the
most significant change since the introduction of additive solutions 25 years ago.
As concern mounts about the clinical impact of storage time of red cell units, reduction
in the storage lesion that accumulates has taken on increased importance. Anaerobic
storage is a new tool that may not only lengthen but improve the storage of these
life-saving cells.”
James AuBuchon, M.D. | President & CEO, Puget Sound Blood Center
| Professor of Medicine & Laboratory Medicine, University of Washington
“It (HVA) is safe, non-invasive and inexpensive to use - characteristics that suggest
HVA will be seen by clinicians and researchers as a very cost effective and valuable
addition to their diagnostic and disease management capabilities.”
Charles Tegler, M.D. | (McKinney-Avant Professor of Neurology,
Wake Forest University)
“NHSi’s HVA platform promises to enhance greatly the relevance and utility of TCD
and other hemodynamic data in the diagnosis and management of neurovascular disease,
and in the development and assessment of therapies for those diseases. I look forward
to continuing my work with NHSi’s leadership to realize its full scientific and
commercial potential.”
Rune Aaslid, Ph.D. | (Department of Neurosurgery, Uni. of Bern,
Switzerland) | Inventor of TCD, author of seminal publications in neurovascular
hemodynamics.
“As a clinician, researcher and instructor in the uses of TCD, I believe that that
HVA represents the most significant advance for the use of ultrasound in neurological
and cerebrovascular disorders since the launch of TCD some 25 years ago. It provides
clinicians and researchers with unrivalled insight into the physiological and hemodynamic
characteristics of neurovascular disorders, as well as the effect of systemic diseases
on the cerebrovascular system. It also informs regarding regional and global hemodynamic
effects, with rapid recognition of hemodynamic patterns, which are difficult if
not impossible to identify and objectively quantify with traditional TCD. This affords
clinicians improved ability to identify, diagnose, and treat patients with a wide
array of conditions caused by or resulting in vascular compromise.”
Charles Tegler, M.D. | (McKinney-Avant Professor of Neurology,
Wake Forest University)
“I have made HVA an integral component of my approach to the diagnosis and management
of this extensively under diagnosed condition (Sleep Apnea), and believe it will
be widely adopted and applied by pulmonologists here in the US and overseas.”
Elliot Stokar, M.D., Pulmonologist | (Medical Specialists – Munster,
IN) | Current beta site user of HVA
“NHSi’s HVA technology offers those involved in the diagnosis and management of
NPH a unique ability to add and integrate physiological insights derived from a
comprehensive neurovascular assessment to and with our assessments of patient gait
and cognitive characteristics. In our pilot trial HVA showed a significant difference
between responders and non-responders to CSF drainage at presentation and after
CSF removal, HVA showed a unique pattern of specific vessel sites that was significantly
different between responders in combination and individually.”
Mark Luciano, M.D., Ph.D. | (Chairman, Section of Pediatric and
Congenital Neurosurgery, Cleveland Clinic)
“In my opinion, HVA is a promising and novel method to aid in the diagnosis and
treatment of several major stroke risk factors such as carotid artery atherosclerosis,
and in interventional treatment of symptomatic carotid disease. In addition, HVA
is a promising technology for monitoring response to therapy in acute stroke patients
in the ER and NICU and for follow up in the outpatient setting. The HVA platform
may have an important role in selecting patients for acute stroke treatments, secondary
stroke prevention therapies and stroke rehabilitation and thus to enhance stroke
outcomes with substantial benefits for patients at a lower cost than conventional
imaging tools used in clinical stroke care.”
Tatjana Rundek, M.D., Ph.D. | (Assistant Professor of Neurology
at the University of Miami)
“[HASP] represents a paradigm shift in the approach to storage of red cells, the
most significant change since the introduction of additive solutions 25 years ago.
As concern mounts about the clinical impact of storage time of red cell units, reduction
in the storage lesion that accumulates has taken on increased importance. Anaerobic
storage is a new tool that may not only lengthen but improve the storage of these
life-saving cells.”
James AuBuchon, M.D. | President & CEO, Puget Sound Blood Center
| Professor of Medicine & Laboratory Medicine, University of Washington